Head and Neck Cancer Patient Population, Management, and Oncologic Outcomes from the COVID-19 Pandemic
The COVID-19 pandemic precipitated drastic changes in cancer care. Its impact on the U.S. head and neck cancer population has yet to be fully understood. This study aims to understand the impact of pandemic-related changes on the head and neck cancer population. An observational study of head and ne...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/31/1/29 |
| _version_ | 1797344384658702336 |
|---|---|
| author | Julie R. Bloom Carlos Rodriguez-Russo Kristin Hsieh Daniel R. Dickstein Ren-Dih Sheu Mayuri Jain Erin Moshier Jerry Liu Vishal Gupta Diana N. Kirke Scott Roof Krzysztof Misiukiewicz Marshall Posner Richard Bakst Kunal K. Sindhu Sonam Sharma |
| author_facet | Julie R. Bloom Carlos Rodriguez-Russo Kristin Hsieh Daniel R. Dickstein Ren-Dih Sheu Mayuri Jain Erin Moshier Jerry Liu Vishal Gupta Diana N. Kirke Scott Roof Krzysztof Misiukiewicz Marshall Posner Richard Bakst Kunal K. Sindhu Sonam Sharma |
| author_sort | Julie R. Bloom |
| collection | DOAJ |
| description | The COVID-19 pandemic precipitated drastic changes in cancer care. Its impact on the U.S. head and neck cancer population has yet to be fully understood. This study aims to understand the impact of pandemic-related changes on the head and neck cancer population. An observational study of head and neck cancer patients at a single institution during the spring of 2020 and 2019 was performed. Clinical characteristics and survival outcomes were analyzed. In 2020, 54 head and neck cancer patients were evaluated in the department of radiation oncology vs. 74 patients seen in 2019; 42% of the patients were female in 2019 versus 24% in 2020 (<i>p</i> = 0.036). The median follow-up time was 19.4 and 31 months for 2020 and 2019, respectively. After adjusting for stage, the relapse-free survival probability at 6 and 12 months was 79% and 69% in 2020 vs. 96% and 89% in 2019, respectively (<i>p</i> = 0.036). There was no significant difference in the overall survival, with 94% and 89% in 2020 and 2019, respectively (<i>p</i> = 0.61). Twenty-one percent of patients received induction chemotherapy in 2020 versus 5% in 2019 (<i>p</i> = 0.011); significantly more treatment incompletions occurred in 2020, 9% vs. 0% in 2019 (<i>p</i> = 0.012). Moreover, the stage-adjusted RFS differed between cohorts, suggesting head and neck cancer patients seen during the initial wave of COVID-19 may experience worse oncologic outcomes. |
| first_indexed | 2024-03-08T11:01:37Z |
| format | Article |
| id | doaj.art-e5ce26a9b96f4243981218cc4358820b |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-08T11:01:37Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-e5ce26a9b96f4243981218cc4358820b2024-01-26T15:57:52ZengMDPI AGCurrent Oncology1198-00521718-77292024-01-0131143644610.3390/curroncol31010029Head and Neck Cancer Patient Population, Management, and Oncologic Outcomes from the COVID-19 PandemicJulie R. Bloom0Carlos Rodriguez-Russo1Kristin Hsieh2Daniel R. Dickstein3Ren-Dih Sheu4Mayuri Jain5Erin Moshier6Jerry Liu7Vishal Gupta8Diana N. Kirke9Scott Roof10Krzysztof Misiukiewicz11Marshall Posner12Richard Bakst13Kunal K. Sindhu14Sonam Sharma15Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USADepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USADepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USADepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USADepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USADepartment of Population Health Science and Policy, Tisch Cancer Institute Biostatistics Shared Resource Facility, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USADepartment of Population Health Science and Policy, Tisch Cancer Institute Biostatistics Shared Resource Facility, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USADepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USADepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USADepartment of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USADepartment of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USADepartment of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USADepartment of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USADepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USADepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USADepartment of Radiation Oncology, Summit Health, Berkeley Heights, NJ 07922, USAThe COVID-19 pandemic precipitated drastic changes in cancer care. Its impact on the U.S. head and neck cancer population has yet to be fully understood. This study aims to understand the impact of pandemic-related changes on the head and neck cancer population. An observational study of head and neck cancer patients at a single institution during the spring of 2020 and 2019 was performed. Clinical characteristics and survival outcomes were analyzed. In 2020, 54 head and neck cancer patients were evaluated in the department of radiation oncology vs. 74 patients seen in 2019; 42% of the patients were female in 2019 versus 24% in 2020 (<i>p</i> = 0.036). The median follow-up time was 19.4 and 31 months for 2020 and 2019, respectively. After adjusting for stage, the relapse-free survival probability at 6 and 12 months was 79% and 69% in 2020 vs. 96% and 89% in 2019, respectively (<i>p</i> = 0.036). There was no significant difference in the overall survival, with 94% and 89% in 2020 and 2019, respectively (<i>p</i> = 0.61). Twenty-one percent of patients received induction chemotherapy in 2020 versus 5% in 2019 (<i>p</i> = 0.011); significantly more treatment incompletions occurred in 2020, 9% vs. 0% in 2019 (<i>p</i> = 0.012). Moreover, the stage-adjusted RFS differed between cohorts, suggesting head and neck cancer patients seen during the initial wave of COVID-19 may experience worse oncologic outcomes.https://www.mdpi.com/1718-7729/31/1/29head and neck cancerradiation therapyCOVID-19induction chemotherapygender disparity |
| spellingShingle | Julie R. Bloom Carlos Rodriguez-Russo Kristin Hsieh Daniel R. Dickstein Ren-Dih Sheu Mayuri Jain Erin Moshier Jerry Liu Vishal Gupta Diana N. Kirke Scott Roof Krzysztof Misiukiewicz Marshall Posner Richard Bakst Kunal K. Sindhu Sonam Sharma Head and Neck Cancer Patient Population, Management, and Oncologic Outcomes from the COVID-19 Pandemic Current Oncology head and neck cancer radiation therapy COVID-19 induction chemotherapy gender disparity |
| title | Head and Neck Cancer Patient Population, Management, and Oncologic Outcomes from the COVID-19 Pandemic |
| title_full | Head and Neck Cancer Patient Population, Management, and Oncologic Outcomes from the COVID-19 Pandemic |
| title_fullStr | Head and Neck Cancer Patient Population, Management, and Oncologic Outcomes from the COVID-19 Pandemic |
| title_full_unstemmed | Head and Neck Cancer Patient Population, Management, and Oncologic Outcomes from the COVID-19 Pandemic |
| title_short | Head and Neck Cancer Patient Population, Management, and Oncologic Outcomes from the COVID-19 Pandemic |
| title_sort | head and neck cancer patient population management and oncologic outcomes from the covid 19 pandemic |
| topic | head and neck cancer radiation therapy COVID-19 induction chemotherapy gender disparity |
| url | https://www.mdpi.com/1718-7729/31/1/29 |
| work_keys_str_mv | AT julierbloom headandneckcancerpatientpopulationmanagementandoncologicoutcomesfromthecovid19pandemic AT carlosrodriguezrusso headandneckcancerpatientpopulationmanagementandoncologicoutcomesfromthecovid19pandemic AT kristinhsieh headandneckcancerpatientpopulationmanagementandoncologicoutcomesfromthecovid19pandemic AT danielrdickstein headandneckcancerpatientpopulationmanagementandoncologicoutcomesfromthecovid19pandemic AT rendihsheu headandneckcancerpatientpopulationmanagementandoncologicoutcomesfromthecovid19pandemic AT mayurijain headandneckcancerpatientpopulationmanagementandoncologicoutcomesfromthecovid19pandemic AT erinmoshier headandneckcancerpatientpopulationmanagementandoncologicoutcomesfromthecovid19pandemic AT jerryliu headandneckcancerpatientpopulationmanagementandoncologicoutcomesfromthecovid19pandemic AT vishalgupta headandneckcancerpatientpopulationmanagementandoncologicoutcomesfromthecovid19pandemic AT dianankirke headandneckcancerpatientpopulationmanagementandoncologicoutcomesfromthecovid19pandemic AT scottroof headandneckcancerpatientpopulationmanagementandoncologicoutcomesfromthecovid19pandemic AT krzysztofmisiukiewicz headandneckcancerpatientpopulationmanagementandoncologicoutcomesfromthecovid19pandemic AT marshallposner headandneckcancerpatientpopulationmanagementandoncologicoutcomesfromthecovid19pandemic AT richardbakst headandneckcancerpatientpopulationmanagementandoncologicoutcomesfromthecovid19pandemic AT kunalksindhu headandneckcancerpatientpopulationmanagementandoncologicoutcomesfromthecovid19pandemic AT sonamsharma headandneckcancerpatientpopulationmanagementandoncologicoutcomesfromthecovid19pandemic |